Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
TD Toronto-Dominion Bank
OTGLF CD Projekt SA
HRL Hormel Foods Corp
IPOF Social Capital Hedosophia Holdings Corp VI
NIO NIO Inc
NRT North European Oil Royalty Trust
JNJ Johnson & Johnson
STAG STAG Industrial Inc
TM Toyota Motor Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Price
Delayed
$1.97
Day's Change
-0.05 (-2.48%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.06
Day's Low
1.94
Volume
(Light)

Today's volume of 5,524,115 shares is on pace to be much lighter than CRBP's 10-day average volume of 13,385,254 shares.

5,524,115

Display:

Providers:

UpdateCancel
6 providers
January 20, 2021
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it will participate in the New...(Globe Newswire)

January 19, 2021
The Little-Known Tech That Could Transform Healthcare

One under-the-radar company looks to be an absolute game-changer for the healthcare industry. That's because, despite "Big Pharma's" massive resources and staggering amounts of spending, no large pharmaceutical company has ever been able to solve...(PR Newswire)

November 12, 2020
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief...(Globe Newswire)

November 10, 2020
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system ("ECS"), today reported financial results for the...(Globe Newswire)

November 09, 2020
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today presented additional data from the...(Globe Newswire)

November 03, 2020
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020

-- Company to host conference call and webcast on Tuesday, November 10 at 8:30 a.m. ET Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.